Status and Update on Cardiac Resynchronization Therapy Trials.
Cardiac imaging
Cardiac resynchronization therapy
Clinical studies
Implantable cardioverter-defibrillator
Implantation
Pacemaker
Journal
Cardiac electrophysiology clinics
ISSN: 1877-9190
Titre abrégé: Card Electrophysiol Clin
Pays: United States
ID NLM: 101549998
Informations de publication
Date de publication:
06 2022
06 2022
Historique:
entrez:
17
6
2022
pubmed:
18
6
2022
medline:
22
6
2022
Statut:
ppublish
Résumé
After decades of clinical use, cardiac resynchronization therapy (CRT) can be considered an established therapy. However, there are multiple open questions to be addressed that shall further improve the proportion of patients responding to CRT. Progress in better understanding the relationship between electrical and mechanical disorder in patients with heart failure with ventricular conduction abnormalities is important. This article presents and discusses ongoing studies in different areas of CRT research, including patient selection by novel diagnostic tools, extension of clinical criteria, left ventricular lead positioning and pacing site selection, optimization of CRT delivery and programming, and selection of device type.
Identifiants
pubmed: 35715089
pii: S1877-9182(21)00118-0
doi: 10.1016/j.ccep.2021.12.007
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
323-343Informations de copyright
Copyright © 2021 Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Disclosure A. Auricchio: consultant to Boston Scientific, Backbeat, Biosense Webster, Cairdac, Corvia, Microport CRM, EPD-Philips, Radcliffe Publisher. He received speaker fees from Abbott, Boston Scientific, Medtronic, and Microport. He participates in clinical trials sponsored by Boston Scientific, Medtronic, EPD-Philips. He has intellectual properties with Boston Scientific, Biosense Webster, and Microport CRM. T. Özkartal: nothing to disclose.